ArticleFrontiers in pharmacology2026
Exploring the anti-diabetic potential of peimisine through bioinformatics analysis and
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ethnopharmacological relevance: Objective: This study aimed to identify key bioactive metabolites from Methods: Metabolites were retrieved from TCMSP. Following ADME screening and literature validation, six metabolites were identified, from which peimisine was selected based on AlogP. Its targets were predicted using multiple databases, followed by GO and KEGG enrichment analyses and disease association analyses. Glucose uptake and gluconeogenesis assays were conducted in HepG2 cells, and key targets were further analyzed via PPI network and molecular docking. Results: Six metabolites were identified, with peimisine selected as the most promising candidate. Bioinformatics analysis predicted 48 potential targets, with enrichment in metabolic pathways and a strong association with T2D. Experimentally, peimisine at 20 μM increased glucose uptake by up to 36.30% and reduced medium glucose by 57.65% under normal conditions; in an insulin-resistance model, it restored uptake by 42.82% and lowered glucose by 15.32%. It also significantly suppressed gluconeogenic enzymes, reducing PEPCK mRNA by 80% and G6PD by 31% relative to control. HSP90AA1 was identified as a central target, with a docking score of -7.9 kJ/mol. Conclusion: Peimisine, a metabolite of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.